Update on the Progress of the CANPAIN Clinical TrialBrief: The main CANPAIN clinical trial’s status remains unclear and is still listed as “Unknown Status” on ClinicalTrials.gov4d ago4d ago
Economics evaluation of CANPAIN Fesability StudyIn October 2018, the UK’s National Institute for Health and Care Excellence (“NICE”) issued a call for evidence to evaluate the safety and…Jun 11, 2024Jun 11, 2024
How CTAi fits an evolving Clinical Trials marketThe global AI in clinical trials market is estimated to be worth $ 2.04 billion in 2024 and expected to grow at compounded annual growth…Feb 6, 20241Feb 6, 20241
ClinTex x DeSciThe scientific landscape is on the cusp of a paradigm shift. Enter Decentralised Science (DeSci), a revolutionary approach that leverages…Jan 19, 2024Jan 19, 2024
ClinTex CTi and DeSci — The FutureClintex CTi and DeSci both work off the idea that scientific knowledge, including clinical trial intelligence, should be accessible.Jan 5, 2024Jan 5, 2024
CTAi Beta Release ImminentWe have been working tirelessly over the previous months on the development of our groundbreaking Clintex CTAi application.Sep 28, 2023Sep 28, 2023
Australian Regulator approves MDMA for PTSD treatmentAustralia made history on July 1, 2023, when it became the first country in the world to prescribe MDMA and psilocybin for therapeutic use…Jul 13, 20231Jul 13, 20231
AI-based Clinical Trials market to grow by 600% before end of the decadeAccording to a new study from Research and Markets, the global market for AI-based clinical trial solutions for patient matching is…Apr 3, 2023Apr 3, 2023
How AI will drive success in Clinical TrialsIt takes up to 15 years and an average total R&D expenditure of $1.5–2 billion USD to bring a single new drug to market. About half of this…Jan 16, 2023Jan 16, 2023